You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Hepatocellular Carcinoma Trial (CD-801)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • (no location specified)
Oct 13, 2023

Health Status of Children Born After Assisted Reproductive

Recruiting
  • Children Born After Assisted Reproductive Technologies
  • +2 more
  • hemogram examination
  • Almaty, Kazakhstan
    Sevara ilmuratova
Oct 17, 2023

Immune Markers in Pediatric ITP

Not yet recruiting
  • ITP - Immune Thrombocytopenia
  • complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.
  • (no location specified)
Oct 17, 2023

CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

Recruiting
  • CD70-positive Advanced Urologic Neoplasms
  • Anti-CD70 CAR-T cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Aug 11, 2023

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Azacitidine Injection
  • +2 more
  • (no location specified)
Oct 15, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

Not yet recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • CD7-CART01
  • (no location specified)
Sep 26, 2023

Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • CD70 CAR-T cells
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Aug 23, 2023

Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +4 more
  • (no location specified)
Oct 23, 2023

Pterygium Trial in Balikesir (Expression of CD44, E-cadherin and PCNA)

Not yet recruiting
  • Pterygium
  • Expression of CD44, E-cadherin and PCNA
  • Balıkesir, Turkey
    Hümeyra Yildirim
Sep 15, 2023

HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)

Recruiting
  • HNSCC
  • +5 more
  • DP CD8 TIL
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Jun 5, 2023

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25

Not yet recruiting
  • The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
  • CD25 prophylaxis
  • (no location specified)
Jun 20, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Solid Tumor, Adult Trial (CF33-CD19 IT, CF33-CD19 IV, Blinatumomab)

Not yet recruiting
  • Solid Tumor, Adult
  • CF33-CD19 IT
  • +2 more
  • (no location specified)
Sep 26, 2023

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

Alterations in CD8aß and CD8aa T Cell Levels in Rheumatoid

Not yet recruiting
  • Rheumatoid Arthritis
  • flow cytometry
  • (no location specified)
Apr 12, 2023

ARDS Trial in Tel-Aviv (EXO-CD24, Placebo)

Recruiting
  • ARDS
  • Tel-Aviv, Israel
    Tel-Aviv Sourasky Medical Center
Jul 7, 2023

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

CD55-Deficient Protein-Losing Enteropathy Trial (Pozelimab)

Available
  • CD55-Deficient Protein-Losing Enteropathy
  • (no location specified)
Aug 14, 2023

Hematologic Diseases, Tumors Trial in Hangzhou (CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation)

Recruiting
  • Hematologic Diseases
  • Neoplasms
  • CD7 CAR-T cells injection
  • Allogeneic hematopoietic stem cell transplantation
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Apr 11, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022